Serum uric acid independently predicts cardiovascular events in advanced nephropathy

American Journal of Nephrology

Volumn 36, Issue 4, 2012, Pages 324-331

  Kanbay, Mehmet ^a   Yilmaz, Mahmut Ilker ^a   Sonmez, Alper ^a   Solak, Yalcin ^b   Saglam, Mutlu ^a   Cakir, Erdinc ^a   Unal, Hilmi Umut ^a   Arslan, Erol ^a   Verim, Samet ^a   Madero, Magdalena ^c   Caglar, Kayser ^a   Oguz, Yusuf ^a   Mcfann, Kim ^d   Johnson, Richard J ^d  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b NECMETTIN ERBAKAN UNIVERSITY   (Turkey)

^c INC Ignacio Chavez ^*  (Mexico)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Chronic kidney disease; Uric acid

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; LOOP DIURETIC AGENT; URIC ACID;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; HYPERURICEMIA; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SURVIVAL RATE; URIC ACID BLOOD LEVEL;

ADULT; AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTENSION, RENAL; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PREDICTIVE VALUE OF TESTS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; STROKE; URIC ACID;

EID: 84866516012     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000342390     Document Type: Article

References (39)

1. Schiffrin EL, Lipman ML, Mann JF: Chronic kidney disease: effects on the cardiovascular system. Circulation 2007; 116: 85-97.
2. Rodriguez-Iturbe B, Correa-Rotter R: Cardiovascular risk factors and prevention of cardiovascular disease in patients with chronic renal disease. Expert Opin Pharmacother 2010; 11: 2687-2698.
3. Kanbay M, Ozkara A, Selcoki Y, Isik B, Turgut F, Bavbek N, Uz E, Akcay A, Yigitoglu R, Covic A: Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol 2007; 39: 1227-1233.
4. Mercuro G, Vitale C, Cerquetani E, Zoncu S, Deidda M, Fini M, Rosano GM: Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cardiol 2004; 94: 932-935.
5. Melendez-Ramirez G, Perez-Mendez O, Lopez- Osorio C, Kuri-Alfaro J, Espinola-Zavaleta N: Effect of the treatment with allopurinol on the endothelial function in patients with hyperuricemia. Endocr Res 2012; 37: 1-6.
6. Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincon A, Arroyo D, Luno J: Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010; 5: 1388-1393.
7. Kanbay M, Yilmaz MI, Sonmez A, Turgut F, Saglam M, Cakir E, Yenicesu M, Covic A, Jalal D, Johnson RJ: Serum uric acid level and endothelial dysfunction in patients with nondiabetic chronic kidney disease. Am J Nephrol 2011; 33: 298-304.
8. Feig DI, Kang DH, Johnson RJ: Uric acid and cardiovascular risk. N Engl J Med 2008; 359: 1811-1821.
9. Feig DI: Uric acid: a novel mediator and marker of risk in chronic kidney disease? Curr Opin Nephrol Hypertens 2009; 18: 526-530.
10. Grayson PC, Kim SY, Lavalley M, Choi HK: Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2011; 63: 102-110.
11. Kodama S, Saito K, Yachi Y, Asumi M, Sugawara A, Totsuka K, Saito A, Sone H: Association between serum uric acid and development of type 2 diabetes. Diabetes Care 2009; 32: 1737-1742.
12. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA: Hyperuricemia and risk of stroke: a systematic review and metaanalysis. Arthritis Rheum 2009; 61: 885-892.
13. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA: Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2010; 62: 170-180.
14. Wheeler JG, Juzwishin KD, Eiriksdottir G, Gudnason V, Danesh J: Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis. PLoS Med 2005; 2:e76.
15. Madero M, Sarnak MJ, Wang X, Greene T, Beck GJ, Kusek JW, Collins AJ, Levey AS, Menon V: Uric acid and long-term outcomes in CKD. Am J Kidney Dis 2009; 53: 796-803.
16. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S1-S201.
17. Daien V, Duny Y, Ribstein J, du Cailar G, Mimran A, Villain M, Daures JP, Fesler P: Treatment of hypertension with renin-angiotensin system inhibitors and renal dysfunction: a systematic review and meta-analysis. Am J Hypertens 2012; 25: 126-132.
18. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ: Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005; 366: 2026-2033.
19. Dogra GK, Watts GF, Herrmann S, Thomas MA, Irish AB: Statin therapy improves brachial artery endothelial function in nephrotic syndrome. Kidney Int 2002; 62: 550-557.
20. Varin R, Mulder P, Tamion F, Richard V, Henry JP, Lallemand F, Lerebours G, Thuillez C: Improvement of endothelial function by chronic angiotensin-converting enzyme inhibition in heart failure: role of nitric oxide, prostanoids, oxidant stress, and bradykinin. Circulation 2000; 102: 351-356.
21. Plantinga Y, Ghiadoni L, Magagna A, Giannarelli C, Franzoni F, Taddei S, Salvetti A: Supplementation with vitamins C and E improves arterial stiffness and endothelial function in essential hypertensive patients. Am J Hypertens 2007; 20: 392-397.
22. Wang XQ, Vaziri ND: Erythropoietin depresses nitric oxide synthase expression by human endothelial cells. Hypertension 1999; 33: 894-899.
23. George J, Carr E, Davies J, Belch JJ, Struthers A: High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006; 114: 2508-2516.
24. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
25. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
26. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
27. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE: Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-1115.
28. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-265.
29. Kang DH, Park SK, Lee IK, Johnson RJ: Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005; 16: 3553-3562.
30. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ: Elevated uric acid increases blood pressure in the rat by a novel crystalindependent mechanism. Hypertension 2001; 38: 1101-1106.
31. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, Krotova K, Block ER, Prabhakar S, Johnson RJ: Hyperuricemia induces endothelial dysfunction. Kidney Int 2005; 67: 1739-1742.
32. Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R, Johnson RJ: A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002; 13: 2888-2897.
33. Chao HH, Liu JC, Lin JW, Chen CH, Wu CH, Cheng TH: Uric acid stimulates endothelin-1 gene expression associated with NADPH oxidase in human aortic smooth muscle cells. Acta Pharmacol Sin 2008; 29: 1301-1312.
34. Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, Wamsley A, Sheikh-Hamad D, Lan HY, Feng L, Johnson RJ: Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 2003; 41: 1287-1293.
35. Cheng TH, Lin JW, Chao HH, Chen YL, Chen CH, Chan P, Liu JC: Uric acid activates extracellular signal-regulated kinases and thereafter endothelin-1 expression in rat cardiac fibroblasts. Int J Cardiol 2010; 139: 42-49.
36. Sarafidis PA, Ruilope LM: Insulin resistance, hyperinsulinemia, and renal injury: mechanisms and implications. Am J Nephrol 2006; 26: 232-244.
37. Fliser D, Pacini G, Engelleiter R, Kautzky- Willer A, Prager R, Franek E, Ritz E: Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 1998; 53: 1343-1347.
38. Garcia RG, Rincon MY, Arenas WD, Silva SY, Reyes LM, Ruiz SL, Ramirez F, Camacho PA, Luengas C, Saaibi JF, Balestrini S, Morillo C, Lopez-Jaramillo P: Hyperinsulinemia is a predictor of new cardiovascular events in Colombian patients with a first myocardial infarction. Int J Cardiol 2011; 148: 85-90.
39. Lakka HM, Lakka TA, Tuomilehto J, Sivenius J, Salonen JT: Hyperinsulinemia and the risk of cardiovascular death and acute coronary and cerebrovascular events in men: the Kuopio Ischaemic Heart Disease Risk Factor Study. Arch Intern Med 2000; 160: 1160-1168.